In a disease with dismal outcomes, KRAS inhibitors may offer hope for treating pancreatic cancer. But with preliminary data, ...

There are already two drugs on the market targeting KRAS mutations, for decades considered an undruggable target, but no shortage of drug candidates hoping to follow them. At ASCO, Eli Lilly ...

Revolution Medicines' promising KRAS inhibitors show potential in treating difficult cancers. Find out whether RVMD stock is ...

Research into targeted TP53 therapies is ongoing. The KRAS mutation is found in about 30% of all NSCLCs. It’s more common in people who smoke. The outlook for people with this type of mutation ...

One of the mutations, tumor protein 53, suppresses tumor growth while the other, known as KRAS, is a driver of proliferation.

Dupert is Innovent’s eleventh product in its commercial portfolio and is anticipated to soon benefit more lung cancer patients with the KRAS G12C mutation. Lung cancer has one of the highest incidence ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

The presented posters “ Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations ” and “ ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Chinese companies Innovent Biologics and GenFleet have recently secured approval from China’s National Medical Products ...

Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for ...